NAUT (nautilus.bio) חובות לטווח קצר של החברה

The success of Nautilus Biotechnology (NAUT) is based on the precision of molecule identification, yet it requires strict control over R&D costs. The current volume of short-term loans demonstrates financial dynamics where the value of 0.00 reflects this working capital status. Meanwhile, the company faces intense pressure from tech giants in the race to implement proteomics tools in laboratories.

This metric aggregates short-term loan and credit obligations, determining the current level of credit pressure on the company's liquidity prior to the next reporting update. For Nautilus Biotechnology (NAUT), which is in the pre-commercial stage of developing its proteomic platform, the dynamics of financial liabilities with maturities of up to 12 months are critical, as the absence of revenue makes the company dependent on external financing until it achieves technological superiority.